Pankaj Bhargava, āshibio CEO

Gilead test­ed an an­ti­body many times. A small biotech sal­vages it, with $40M and ‘con­vic­tion’ else­where

Gilead had test­ed a hu­man­ized an­ti­body called an­de­cal­ix­imab, or GS-5745, in close to 1,000 pa­tients be­fore giv­ing up on it a few years ago. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.